Literature DB >> 21631148

New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model.

Jan Poleszczuk1, Marek Bodnar, Urszula Foryś.   

Abstract

In the paper we propose a new methodology in modeling of antiangiogenic treatment on the basis of well recognized model formulated by Hahnfeldt et al. in 1999. On the basis of the Hahnfeldt et al. model, with the usage of the optimal control theory, some protocols of antiangiogenic treatment were proposed. However, in our opinion the formulation of that model is valid only for the antivascular treatment, that is treatment that is focused on destroying endothelial cells. Therefore, we propose a modification of the original model which is valid in the case of the antiangiogenic treatment, that is treatment which is focused on blocking angiogenic signaling. We analyze basic mathematical properties of the proposed model and present some numerical simulations.

Mesh:

Substances:

Year:  2011        PMID: 21631148     DOI: 10.3934/mbe.2011.8.591

Source DB:  PubMed          Journal:  Math Biosci Eng        ISSN: 1547-1063            Impact factor:   2.080


  5 in total

1.  Therapeutic implications from sensitivity analysis of tumor angiogenesis models.

Authors:  Jan Poleszczuk; Philip Hahnfeldt; Heiko Enderling
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

2.  Deterministic and Stochastic Study for a Microscopic Angiogenesis Model: Applications to the Lewis Lung Carcinoma.

Authors:  Marek Bodnar; Pilar Guerrero; Ruben Perez-Carrasco; Monika J Piotrowska
Journal:  PLoS One       Date:  2016-05-16       Impact factor: 3.240

3.  Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data.

Authors:  Katerina D Argyri; Dimitra D Dionysiou; Fay D Misichroni; Georgios S Stamatakos
Journal:  Biol Direct       Date:  2016-03-22       Impact factor: 4.540

4.  Workflow-driven clinical decision support for personalized oncology.

Authors:  Anca Bucur; Jasper van Leeuwen; Nikolaos Christodoulou; Kamana Sigdel; Katerina Argyri; Lefteris Koumakis; Norbert Graf; Georgios Stamatakos
Journal:  BMC Med Inform Decis Mak       Date:  2016-07-21       Impact factor: 2.796

5.  Anti-angiogenic drug scheduling optimisation with application to colorectal cancer.

Authors:  M Sturrock; I S Miller; G Kang; N Hannis Arba'ie; A C O'Farrell; A Barat; G Marston; P L Coletta; A T Byrne; J H Prehn
Journal:  Sci Rep       Date:  2018-07-25       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.